Welcome to Zilico

Introducing the next generation of diagnostics

Zilico Ltd is a company developing the next generation of diagnostics with a product line which will provide real-time results.  Zilico has developed Electrical Impedance Spectroscopy EIS, an objective scientifically-proven method to differentiate between normal and pre cancerous and cancerous tissues (neoplasias), into a technology that can address the need for improved detection and diagnosis of neoplasia.

The primary clinical focus is within the cervical cancer diagnostic pathway.  Zilico's lead product, ZedScan I is aimed at  patients referred after an initial test. A second product is being developed for the initial screening of women.

ZedScan I addresses the needs of the referral population, will reduce the number of biopsies taken and has the potential to facilitate the wider use of ‘see & treat’ modality.   Clinical data on 1000 patients has demonstrated superior performance over existing diagnostic procedures.

Zilico’s patented technology exploits the different electrical resistivity of normal, pre-cancerous and cancerous tissue cellular structures and is therefore applicable to other types of neoplasia.  The Company has recently embarked on a proof-of-concept 50 patient trial for detecting neoplasia in oral lesions.

The early research was carried out at the Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield.  Zilico has focused on developing a research-based instrument into a device appropriate for commercial manufacture and routine use by medical practitioners.

ZedScan I consists of a handheld device and a base unit together with a single-use EIS sensor.